Medicenna Announces Appointment of New Auditor

TORONTO and HOUSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the appointment of MNP LLP (“MNP” or “Successor Auditor”) as auditor. The board of directors of the Company accepted the resignation of PricewaterhouseCooper LLP (the “Former Auditor”) and appointed MNP as the new auditor until the next annual general meeting of shareholders of the Company.

Go here to see the original:
Medicenna Announces Appointment of New Auditor